Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Ataxia Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GRID2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GRID2 Recombinant Protein (ECD/LBD) High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed for native glycosylation. |
View GRID2 Products |
| Gene Delivery | GRID2 Lentivirus Premade Particles Full-length ORF for stable cell line construction. Crucial for preserving native multi-pass transmembrane conformation. |
View GRID2 Products |
| Benchmark Ab | Anti-GRID2 Recombinant Antibody Recombinant positive control for validation assays. |
View GRID2 Products |
| Validator | GRID2 siRNA Set For target knockdown and specificity verification. |
View GRID2 Products |
| Related Target A | GRID1 Subfamily homolog. Essential for counter-screening to ensure drug selectivity. |
View GRID1 Products |
| Related Target B | CBLN1 Extracellular organizer that binds GRID2 to regulate synaptic plasticity. |
View CBLN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-pass Membrane Protein | Lentivirus-driven stable cell line expression to preserve native ion channel tertiary structure. |
| Subfamily Off-target Screening (GRID1 vs GRID2) | High-purity homolog panel proteins strictly verified by mass spectrometry and sequence analysis. |
| Lack of Controls | Sequence-defined recombinant benchmark antibodies included. |
| False Positives in Phenotypic Assays | Sequence-verified siRNA sets included for target knockdown validation. |
Live GRID2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GRID2 therapeutics is intensifying, with major players shifting focus from traditional small molecules to gene therapy and targeted synaptic modulators. As first-generation therapies for cerebellar ataxia reach preclinical and early clinical milestones, the next wave of R&D is targeting precise synaptic reconstruction. GRID2 (Glutamate Ionotropic Receptor Delta Subunit 2) is highly localized in Purkinje cells, making it a high-value target for spinocerebellar ataxias (SCAs) and neurodevelopmental disorders. Current drug discovery efforts focus on restoring channel function or modulating the tripartite synaptic complex (Neurexin-Cerebellin-GRID2).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lenti) | Academic Medical Centers, Biotech Startups | Spinocerebellar Ataxia, Neurodevelopmental Disorders | High-titer Lentivirus for stable expression and conformation-preserved cell-based assays. |
| Small Molecule (PAMs/NAMs) | Neuroscience-focused Pharma | Cerebellar Dysfunction, Synaptic Atrophy | Selectivity profiling using GRID1 vs GRID2 recombinant extracellular domains. |
| Biologics (Synaptic Organizers) | Translational Neurology Labs | Synaptic Repair, Cognitive Deficits | High-purity CBLN1 and GRID2 ECD-Fc proteins for protein-protein interaction (PPI) assays. |